Open Orphan plc changed its name to hVIVO plc on 26 October 2022, learn more here.

Articles & Research
from hVIVO

Scientific Paper

Treatment with the P2X3-Receptor Antagonist Gefapixant for Acute Cough in Induced Viral Upper Respiratory Tract Infection: A Phase 2a, Randomized, Placebo-Controlled Trial

RSV Human Challenge Study as a tool for a break-through designation

An international biotech company, headquartered in the EU approached hVIVO to explore the possibility of performing a RSV Phase IIa challenge study. The investigational product was a novel recombinant modified...

Infectious Diseases Blog – ‘The Pathogenda’ Part 5

In one of the most important discoveries in medicine this year, Epstein-Barr virus (EBV) has been collared as the link/early causal role in multiple sclerosis. Finding the virus underpinning multiple...

Infectious Diseases Blog – ‘The Pathogenda’ Part 4

So we know, or at least it is being widely reported, that depression and anxiety indices are raised worldwide, and most especially in High Income Countries (HIC). Whilst this is...

Scientific Paper

Human infection studies: Key considerations for challenge agent development and production

Infectious Diseases Blog – ‘The Pathogenda’ Part 3

Spring continues to bring its oft’ mixed blessings of sunshine and showers, as expressed over four hundred years ago in this short poem by Thomas Tusser in ‘A Hundred Good...

Infectious Diseases Blog – ‘The Pathogenda’ Part 2

Hello and welcome all to a sunny spring but one somewhat diminished in its capacity for ‘joy in the morning’ by a vicious uptick in BA.2 infections globally, with the...

Scientific Paper

Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults

Infectious Diseases Blog – ‘The Pathogenda’ Part 1

Scientific Paper

EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge